Not Applicable.
This invention relates to prosthetic devices for implantation within a bone, and more particularly to support structures that are affixed to a bone and that support prosthetic implants.
The replacement of joints, such as the shoulder, hip, knee, ankle and wrist, with prosthetic implants has become widespread. One problem commonly encountered by surgeons replacing joints is the loss of strong bone stock near the joint being replaced. Defects in a bone adjacent a joint, such as the hip or knee, can occur due to wear and arthritis of the joint, congenital deformity, and following the removal of a failed prosthetic implant. Defects can be of a cavitary contained type or segmental and uncontained. Because such bone defects are quite common, various methods have been proposed for minimizing the adverse effects of such bone defects on joint replacement procedures.
It is known to use bone graft to prepare a support surface for a prosthesis, either with or without the use of cement. A bone grafting procedure is often used where there is an appreciable loss of strong bone stock, as is often the case in revision surgery where a previously implanted prosthesis is replaced with a new prosthesis. The support surface prepared with bone graft may be made up entirely of bone graft to substantially surround a prosthesis, or the support surface may be made up of bone graft and the natural bone at the implantation site (for instance, where bone graft is used to fill a relatively small void in the natural bone where the bone is otherwise intact). Bone graft typically includes crushed bone (cancellous and cortical), or a combination of these and synthetic biocompatible materials. Bone graft of this type is intended to stimulate growth of healthy bone. Examples of bone graft materials and related materials can be found in U.S. Pat. Nos. 5,972,368, 5,788,976, 5,531,791, 5,510,396, 5,356,629, 4,789,663 and 4,678,470. Bone graft may be positioned in a bone cavity by various methods such as those described in U.S. Pat. Nos. 6,142,998, 6,013,080 and 5,910,172. The use of bone graft to prepare a support surface for a prosthesis does have certain disadvantages as bone graft may not be readily available in all areas and the devices used to deliver bone graft can be quite cumbersome.
In the presence of bone deficiency, stemmed components are also often used as a method to augment prosthesis fixation during complex primary or revision knee and hip arthroplasty. These stems may be cemented or uncemented; however, the most common method of fixation during revision knee arthroplasty is the use of an uncemented stem combined with cement fixation of the prosthesis in the metaphyseal region. However, due to the large variation of bone quality, interdigitation of bone cement into the metaphyseal region is often suboptimal such that cement fixation of the stem in the bone cavity is necessary. While cement fixation of the stem provides for improved prosthesis fixation, it does have disadvantages. For example, one recognized problem with the use of a cemented stem is that the transfer of stress from the implant to the bone is abnormal. Instead of a normal loading of the bone primarily at the end of the bone near the joint surface, the bone is loaded more distally where the stem of the implant is affixed to the bone. This results in the well known phenomenon called “stress shielding” in which the load (i.e., stress) bypasses or “unloads” the end of the joint surface portion of the bone.
In the presence of severe bone deficiency, the diaphyseal region of the bone is often deficient or absent and requires the use of bone graft or unique prosthetic designs to achieve adequate prosthesis fixation during complex primary or revision knee and hip arthroplasty. The use of large structural allografts to restore bone stock requires a sophisticated bone banking system and is associated with the potential transmission of viral or bacterial pathogens. Furthermore, the difficulties with sizing and bone graft preparation are cumbersome and inexact.
When the bone deficiency occurs at the end surface of a bone, prosthetic implant augmentation devices are also often used. Typically, these devices comprise an implant body and a spacer that is attached to the implant body to form a bearing surface on the implant. The implant is affixed to the bone with the bearing surface resting on the end of the bone, essentially acting as a replacement for lost bone. U.S. Pat. Nos. 5,480,445, 5,387,241, 5,152,797 and 5,019,103 show examples of such devices. While these types of implant augmentation devices provide one solution to the problems associated with the implantation of a prosthesis in the end surface of a bone with inadequate bone stock, these implant augmentation devices can only be used with specific implants available from selected implant manufacturers.
In the context of hip arthroplasty, oversized acetabular components and morselized bone grafts have been used to restore bone deficiencies, but larger defects have in the past been associated with a high failure rate despite efforts at reconstruction using large solid structural allografts or custom acetabular components. These devices gain support against the residual bone of the pelvis but often lack adequate bony support for long term mechanical durability.
Therefore, there is a need for alternative prosthetic implant support structures that do not rely on the use of large amounts of bone graft or cumbersome bone graft delivery devices. There is also a need for prosthetic implant support structures that can eliminate the need to cement the distal portion of the stem of an implant to the inner surface of a bone cavity. In addition, there is a need for prosthetic implant support structures that can be used with a wide variety of prosthetic implants obtained from any number of different implant manufacturers. Furthermore, there is a need for a prosthetic implant system that optimizes implant support on intact host bone with minimal removal of residual host bone and that encourages bone ingrowth and attachment over as large a surface area as possible.
The foregoing needs are met by a prosthetic system according to the invention that is implanted in a cavity in an end of a bone. The prosthetic system includes a prosthetic implant and a support structure secured to an inner surface of the cavity in the end of the bone. The support structure defines an axial channel that extends through the length of the support structure. The prosthetic implant is received in the channel of the support structure, and a portion of the prosthetic implant is secured to an inner surface of the channel of the support structure by an adhesive.
In one version of the invention, the support structure comprises a hollow sleeve having a sloped outer surface such that the length of a first perimeter of one end of the sleeve is greater than the length of a second perimeter at an opposite end of the sleeve. Such a support structure may have an approximately funnel shape. At the junction of the metaphysis and diaphysis of a bone such as the femur or tibia, the bone defect is often funnel shaped. Accordingly, a funnel shaped support structure in accordance with the invention can be impacted into the distal femur or proximal tibia so that the external geometry of the funnel shaped support structure is firmly wedged in the metaphyseal-diaphyseal junction of the bone. The internal portion of the funnel shaped support structure provides an access channel that allows passage of the stem extending from a traditional prosthesis of any prosthetic design or manufacturer. The stem of the prosthesis is cemented to the inner surface of the access channel using bone cement, and the stem extension beyond the funnel shaped support structure may be cemented or uncemented.
In another version of the invention, the support structure comprises a hollow porous cylindrical sleeve. The sleeve can be inserted into a large cavernous diaphyseal bone defect or can be used as a replacement for segmental or complete diaphyseal bone deficiency. The sleeve can be a number of different sizes and lengths so that a surgeon can pick the appropriate sized sleeve for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. The sleeve can accommodate any number of prosthetic designs and can achieve fixation to remaining host tissue by soft tissue or bone ingrowth. A stem of a prosthesis is fixed within the sleeve by use of bone cement, and the stem of the prosthesis beyond the sleeve may be cemented or uncemented.
In yet another version of the invention, the support structure comprises a pair of components arranged in spaced apart relationship thereby defining a channel between the pair of components. The support structure may be based on hemispherical shapes (such as a configuration approximating a quarter of a sphere) which are provided in a range of sizes for the creation of a prosthetic foundation for support of standard tibial, femoral, or acetabular components. While this support structure is particularly useful in the acetabulum and hip, the support structure is appropriate for all joints undergoing prosthetic replacement with a wide range of shapes and sizes necessary for management of defects in different locations. The support structure is compatible with a range of standard implant designs currently available from a variety of manufacturers. The interface between the pair of components and the prosthetic implant is cemented with bone cement. All surfaces against host bone may be uncemented and are available for bone ingrowth into porous materials used for the components. Optionally, morselized cancellous bone may be placed into fenestrations in the pair of components and supplemental screw fixation of the pair of components to bone may be used to encourage bone ingrowth and secure fixation to host bone over the long term.
In still another version of the invention, the support structure comprises a plurality of pedestals secured to the inner surface of the cavity of the bone. Each pedestal comprises a flat body section and a stem section extending substantially perpendicularly from the body section. The stem section of each pedestal is secured to the inner surface of the cavity of the bone, and the flat body sections of the pedestals are secured to a portion of a bearing surface of the prosthetic implant. The support structure may further comprise bone graft material surrounding the plurality of pedestals. In one form, the pedestals and the bone graft material are arranged in a circular arrangement whereby the channel that extends through the length of the support structure is circular. A stem of a prosthesis is fixed within the channel by use of bone cement, and the stem of the prosthesis beyond the channel may be cemented or uncemented.
It is therefore an advantage of the present invention to provide prosthetic implant support structures that do not rely on the use of large amounts of bone graft or cumbersome bone graft delivery devices.
It is another advantage of the present invention to provide prosthetic implant support structures that can eliminate the need to cement the distal portion of the stem of an implant to the inner surface of a bone cavity.
It is a further advantage of the present invention to provide prosthetic implant support structures that can be used with a wide variety of prosthetic implants obtained from any number of different implant manufacturers.
It is yet another advantage of the present invention to provide a prosthetic implant system that optimizes implant support on intact host bone with minimal removal of residual host bone and that encourages bone ingrowth and attachment over as large a surface area as possible.
These and other features, aspects, and advantages of the present invention will become better understood upon consideration of the following detailed description, drawings, and appended claims.
It should be understood that the drawings are not necessarily to scale and that the embodiments are sometimes illustrated by diagrammatic representations and fragmentary views. In certain instances, details which are not necessary for an understanding of the present invention or which render other details difficult to perceive may have been omitted. It should be understood, of course, that the invention is not necessarily limited to the specific embodiments illustrated herein.
Like reference numerals will be used to refer to like or similar parts from Figure to Figure in the following description of the drawings.
The present invention is directed to a prosthetic system that includes a prosthetic implant and a support structure secured to an inner surface of the cavity in the end of the bone. The prosthetic system and the methods for its use are illustrated and described herein with reference to the replacement of a hip joint or a knee joint. However, it should be understood that the methods and prosthetic systems according to the invention can be used in the repair of any bone or in connection with the implantation of prosthetic devices at or in any bone in the body, adjacent to or remote from any joint, including without limitation the hip, knee and spinal joints. Further, the methods and prosthetic systems according to the invention can be used in primary surgery, in which a prosthesis is being used to reconstruct a joint for the first time, as well as in revision surgery, in which a previously-implanted prosthesis is being replaced with another prosthesis. Press fit, cement or other fixation techniques can be employed in conjunction with the methods and prosthetic systems according to the invention.
Looking first at
Referring to
The funnel shaped sleeve 40 defines an axial access channel 46 that extends through the length of the funnel shaped sleeve 40. The funnel shaped sleeve 40 has a top end surface 41, an outer surface 42, and an inner surface 47 of the access channel 46. In the version of the funnel shaped sleeve 40 shown, the outer surface 42 of the funnel shaped sleeve 40 is sloped such that the length of a top end perimeter 43 of the funnel shaped sleeve 40 is greater than the length of a bottom end perimeter 44 at an opposite end of the funnel shaped sleeve 40. The inner surface 47 of the access channel 46 may be similarly sloped if desired. The funnel shaped sleeve 40 may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, the funnel shaped sleeve 40 is formed from a metal alloy.
The outer surface 42 of the funnel shaped sleeve 40 may be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between the funnel shaped sleeve 40 and the inner surface 4 of the medullary canal (cavity) 3 of the end portion 5 of the tibia 2 within which the funnel shaped sleeve 40 is implanted. The inner surface 47 of the access channel 46 of the funnel shaped sleeve 40 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 41 of the funnel shaped sleeve 40 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. The funnel shaped sleeve 40 may have a variety of shapes and sizes, which vary by height, width and depth. A surgeon can use conventional measurement tools to select the height, width and depth of the funnel shaped sleeve 40.
The prosthetic system shown in
Looking at
Because the funnel shaped sleeve 40 is not an integral component of the tibial implant 20, the funnel shaped sleeve 40 can be used with any stemmed prosthesis regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
In the presence of severe bone deficiency, the diaphyseal region of a bone is often deficient or absent and often requires the use of bone graft or unique prosthetic designs to achieve adequate prosthesis fixation during complex primary or revision knee and hip arthroplasty. As detailed above, the use of large structural allografts to restore bone stock requires a sophisticated bone banking system and is associated with the potential transmission of viral or bacterial pathogens. Furthermore, the difficulties with sizing and bone graft preparation are cumbersome and inexact. The advantages of minimizing disease transmission by minimizing use of allograft material and reduced operative times can be achieved with another prosthetic system according to the invention as shown in
Referring now to
Referring to
The cylindrical sleeve 50 defines an axial access channel 57 that extends through the length of the cylindrical sleeve 50. The cylindrical sleeve 50 has a top end surface 52, an outer surface 54, and an inner surface 58 of the access channel 57. The cylindrical sleeve 50 has a cylindrical upper section 51 having a first outside diameter and a cylindrical lower section 55 having a second outside diameter less than the first outside diameter. The access channel 57 may be cylindrical or optionally, the access channel 57 may be configured to accept various implant stem designs. For example, it can be seen from
The outer surface 54 of the cylindrical sleeve 50 may also be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between the cylindrical sleeve 50 and the inner surface 10 of the medullary canal (cavity) 9 of the femur 8 within which the cylindrical sleeve 50 is implanted. The inner surface 58 of the access channel 57 of the cylindrical sleeve 50 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 52 of the cylindrical sleeve 50 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. The cylindrical sleeve 50 may comprise any number of different sizes and lengths so that a surgeon is able to pick the appropriate sized sleeve for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. A surgeon can use conventional measurement tools to select the length and width of the cylindrical sleeve 50.
The prosthetic system shown in
Looking at
Because the cylindrical sleeve 50 is not an integral component of the femoral implant 28, the cylindrical sleeve 50 can be used with any stemmed prosthesis regardless of manufacturer or prosthetic design. The sleeve can accommodate any number of prosthetic designs and achieves fixation to remaining host tissue by soft tissue or bone ingrowth. Further, it should be noted that the example given in
Turning now to
Referring to
The periprosthetic support structure 80 comprises a plurality of pedestals 81 that are impacted into or cemented to the inner surface 4 of the medullary canal (cavity) 3 of the end portion 5 of a tibia 2. Each pedestal 81 includes a flat disk shaped body section 82 having a top surface 83 and a stem section 84 extending substantially perpendicularly from the body section 82. The stem section 84 optionally includes a pointed end section 85 that facilitates impaction into the inner surface 4 of the medullary canal (cavity) 3 of the end portion 5 of a tibia 2. Each pedestal 81 may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, each pedestal 81 is formed from a metal alloy. The outer surfaces of each pedestal 81 (including the top surface 83) may be provided with a rough or corrugated surface finish to facilitate the interdigitation of bone cement. The body section 82 of each pedestal 80 may have a variety of shapes and sizes as long as there exists a generally flat portion on part of the top surface. The stem section 84 of each pedestal 81 may also have various lengths and widths. A surgeon can use conventional measurement tools to select the dimensions of each pedestal 81.
The pedestals 81 may be implanted in a bone as follows to form the periprosthetic support structure 80. First, the end portion 5 of the tibia 2 is inspected and tools (such as a reamer) may be used to clean material out of the medullary canal (cavity) 3 or the bone defect 7 (if any). Once the medullary canal (cavity) 3 and the bone defect 7 have been prepared, the stem section 84 of each pedestal 81 is impacted into or cemented onto the end portion 5 of the tibia 2 to form the periprosthetic support structure 80. The pedestals 81 may be arranged in any configuration; however, it is preferred that the pedestals 81 are arranged in the circular arrangement shown in
After the periprosthetic support structure 80 is formed in a bone, the stem 24 of the tibial implant 20 may be moved into the access channel 86 of the periprosthetic support structure 80. As shown in
Looking at
Because the periprosthetic support structure 80 is not an integral component of the tibial implant 20, the periprosthetic support structure 80 can be used with any stemmed prosthesis regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
Referring now to
Each support component 61c may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, each support component 61c is formed from a metal alloy.
The outer surface 63c of each support component 61c may also be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between each support component 61c and the inner surface 16 of the acetabular cavity 15 of a hip bone 14 within which each support component 61c is implanted. The inner surface 64c of each support component 61c has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 62c of each support component 61c has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Each support component 61c also has fenestrations 65c which can be filled with bone graft material (e.g., morselized cancellous bone).
Each support component 61c may comprise any number of different heights, widths and depths so that a surgeon is able to pick the appropriate sized support component for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. A surgeon can use conventional measurement tools to select the size of each support component 61c. The size, position and orientation of each support component 61c and the use of supplemental screw fixation for each support component 61c is dependent on the size and location of the defects in the host bone as well as the quality of the bone that remains.
The support components 61c may be implanted in a bone as follows to form the periprosthetic support structure 60c. First, the acetabular cavity 15 of the hip bone 14 is inspected and tools (such as a reamer) may be used to clean material out of the acetabular cavity 15. Once the acetabular cavity 15 has been prepared, each support component 61c is impacted into or cemented onto the end portion 17 of the acetabular cavity 15 of the hip bone 14 in spaced apart relationship to form the periprosthetic support structure 60c. Preferably, each support component 61c is not cemented to the hip bone and therefore is available for bone ingrowth into the textured outer surface 63c of the support component 61c. The support components 61c shown in
After the periprosthetic support structure 60c is constructed in a bone, the acetabular cup implant 36 may be placed into the access channel 68c of the periprosthetic support structure 60c. Placement can occur either during the same operative procedure as support component 61c placement or can be performed later once bone union to the support components 61c has occurred. In either instance, the acetabular cup implant 36 would be placed only after the acetabulum had been reconstructed using the support structure 60c. As shown in
Because the periprosthetic support structure 60c is not an integral component of the acetabular cup implant 36, the periprosthetic support structure 60c can be used with any acetabular cup implant 36 regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
Referring now to
Each support component 61b may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, each support component 61b is formed from a metal alloy.
The outer surface 63b of each support component 61b may also be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between each support component 61b and the inner surface 16 of the acetabular cavity 15 of a hip bone 14 within which each support component 61b is implanted. The inner surface 64b of each support component 61b has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 62b of each support component 61b has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Each support component 61b also has fenestrations 65b which can be filled with bone graft material (e.g., morselized cancellous bone).
Each support component 61b may comprise any number of different heights, widths and depths so that a surgeon is able to pick the appropriate sized support component for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. A surgeon can use conventional measurement tools to select the size of each support component 65c. The size, position and orientation of each support component 61b is dependent on the size and location of the defects in the host bone as well as the quality of the bone that remains.
The support components 61b may be implanted in a bone as follows to form the periprosthetic support structure 60b. First, the acetabular cavity 15 of the hip bone 14 is inspected and tools (such as a reamer) may be used to clean material out of the acetabular cavity 15. Once the acetabular cavity 15 has been prepared, each support component 61b is impacted into or cemented onto the end portion 17 of the acetabular cavity 15 of the hip bone 14 in spaced apart relationship to form the periprosthetic support structure 60b. Preferably, each support component 61b is not cemented to the hip bone and therefore is available for bone ingrowth into the textured outer surface 63b of the support component 61b. The support components 61b may be arranged in any configuration that creates an access channel 68b that extends through the length of the periprosthetic support structure 60b. Preferably, the support components 61b are arranged to form a substantially hemispherical support structure. It can be seen that placement of the support components 65c precedes placement of any prosthetic joint components.
After the periprosthetic support structure 60b is constructed in a bone, the acetabular cup implant 36 may be placed into the access channel 68b of the periprosthetic support structure 60b. Placement can occur either during the same operative procedure as support component 61b placement or can be performed later once bone union to the support components 61b has occurred. In either instance, the acetabular cup implant 36 would be placed only after the acetabulum had been reconstructed using the support structure 60b. As shown in
Because the periprosthetic support structure 60b is not an integral component of the acetabular cup implant 36, the periprosthetic support structure 60b can be used with any acetabular cup implant 36 regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
Referring now to
Each support component 61a may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, each support component 61a is formed from a metal alloy.
The outer surface 63a of each support component 61a may also be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between each support component 61a and the inner surface 16 of the acetabular cavity 15 of a hip bone 14 within which each support component 61a is implanted. The inner surface 64a of each support component 61a has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 62a of each support component 61a has a rough or corrugated surface finish to facilitate the interdigitation of bone cement.
Each support component 61a may comprise any number of different heights, widths and depths so that a surgeon is able to pick the appropriate sized support component for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. A surgeon can use conventional measurement tools to select the size of each support component 61a. The size, position and orientation of each support component 61a is dependent on the size and location of the defects in the host bone as well as the quality of the bone that remains.
The support components 61a may be implanted in a bone as follows to form the periprosthetic support structure 60a. First, the acetabular cavity 15 of the hip bone 14 is inspected and tools (such as a reamer) may be used to clean material out of the acetabular cavity 15. Once the acetabular cavity 15 has been prepared, each support component 61a is impacted into or cemented onto the end portion 17 of the acetabular cavity 15 of the hip bone 14 in spaced apart relationship to form the periprosthetic support structure 60a. Preferably, each support component 61a is not cemented to the hip bone and therefore is available for bone ingrowth into the textured outer surface 63a of the support component 61a. The support components 61a may be arranged in any configuration that creates an access channel 68a that extends through the length of the periprosthetic support structure 60a. Preferably, the support components 61a are arranged to form a substantially hemispherical support structure. It can be seen that placement of the support components 61a precedes placement of any prosthetic joint components.
After the periprosthetic support structure 60a is constructed in a bone, the acetabular cup implant 36 may be placed into the access channel 68a of the periprosthetic support structure 60a. Placement can occur either during the same operative procedure as support component 61a placement or can be performed later once bone union to the support components 61a has occurred. In either instance, the acetabular cup implant 36 would be placed only after the acetabulum had been reconstructed using the support structure 60a. As shown in
Because the periprosthetic support structure 60a is not an integral component of the acetabular cup implant 36, the periprosthetic support structure 60a can be used with any acetabular cup implant 36 regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
Referring now to
Each support component 71 may be formed from a metal alloy such as titanium alloys (e.g., titanium-6-aluminum-4-vanadium), cobalt-chromium alloys, stainless steel alloys and tantalum alloys; nonresorbable ceramics such as aluminum oxide and zirconia; nonresorbable polymeric materials such as polyethylene; or composite materials such as carbon fiber-reinforced polymers (e.g., polysulfone). Preferably, each support component 71 is formed from a metal alloy.
The outer surface 73 of each support component 71 may also be provided with a metallic texture coating which provides a textured surface so as to attain the desired fixation (by way of tissue ingrowth) between each support component 71 and the inner surface 16 of the acetabular cavity 15 of a hip bone 14 within which each support component 71 is implanted. The inner surface 74 of each support component 71 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Likewise, the top end surface 72 of each support component 71 has a rough or corrugated surface finish to facilitate the interdigitation of bone cement. Each support component 71 may comprise any number of different heights, widths and depths so that a surgeon is able to pick the appropriate sized support component for the patient after intraoperative assessment and thereby avoid difficulties of size mismatch and bone graft contouring. A surgeon can use conventional measurement tools to select the size of each support component 71.
The support components 71 may be implanted in a bone as follows to form the periprosthetic support structure 70. First, the acetabular cavity 15 of the hip bone 14 is inspected and tools (such as a reamer) may be used to clean material out of the acetabular cavity 15. Once the acetabular cavity 15 has been prepared, each support component 71 is placed into, impacted into, or cemented onto the end portion 17 of the acetabular cavity 15 of the hip bone 14 in spaced apart relationship to form the periprosthetic support structure 70. The support components 71 shown in
After the periprosthetic support structure 70 is constructed in a bone, the acetabular cup implant 36 may be placed into the access channel 77 of the periprosthetic support structure 70. Placement can occur either during the same operative procedure as support component 71 placement or can be performed later once bone union to the support components 71 has occurred. In either instance, the acetabular cup implant 36 would be placed only after the acetabulum had been reconstructed using the support structure 70. As shown in
Because the periprosthetic support structure 70 is not an integral component of the acetabular cup implant 36, the periprosthetic support structure 70 can be used with any acetabular cup implant 36 regardless of manufacturer or prosthetic design. Further, it should be noted that the example given in
Therefore, the present invention provides prosthetic implant support structures that solve the problems associated with the loss of strong bone stock near a joint being replaced with a prosthesis. The described prosthetic implant support structures do not rely on the use of large amounts of bone graft or cumbersome bone graft delivery devices. The prosthetic implant support structures can eliminate the need to cement the distal portion of the stem of an implant to the inner surface of a bone cavity and can be used with a wide variety of prosthetic implants obtained from any number of different implant manufacturers. Furthermore, the described prosthetic implant system can optimize implant support on intact host bone with minimal removal of residual host bone and encourages bone ingrowth and attachment over as large a surface area as possible.
While the implantation of tibial, femoral, and acetabular prostheses has been illustrated and described herein, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which have been presented for purposes of illustration and not of limitation. For instance, the methods and prostheses according to the invention can be used in the repair of any bone or in connection with the implantation of prosthetic devices at or in any bone in the body. Accordingly, the scope of the appended claims should not be limited to the description of the embodiments contained herein.
This is a continuation application of U.S. patent application Ser. No. 12/946,132 filed Nov. 15, 2010, now issued as U.S. Pat. No. 8,728,168, which is a continuation application of U.S. patent application Ser. No. 11/560,276 filed Nov. 15, 2006, now U.S. Pat. No. 10,201,426, which is a divisional application of U.S. patent application Ser. No. 10/225,774 filed Aug. 22, 2002, now abandoned, which claims the benefit of U.S. Provisional Patent Application No. 60/315,148 filed Aug. 27, 2001, the disclosures of which are hereby incorporated by reference herein in theft entireties.
Number | Name | Date | Kind |
---|---|---|---|
2947308 | Gorman | Aug 1960 | A |
3605123 | Hahn | Sep 1971 | A |
3658056 | Huggler et al. | Apr 1972 | A |
D230429 | Davidson et al. | Feb 1974 | S |
3855638 | Pilliar | Dec 1974 | A |
3871031 | Boutin | Mar 1975 | A |
3891997 | Herbert | Jul 1975 | A |
3903549 | Deyerle | Sep 1975 | A |
3906550 | Rostoker et al. | Sep 1975 | A |
3918102 | Eichler | Nov 1975 | A |
4064567 | Burstein et al. | Dec 1977 | A |
4136405 | Pastrick et al. | Jan 1979 | A |
4164794 | Spector et al. | Aug 1979 | A |
4206516 | Pilliar | Jun 1980 | A |
4216549 | Hillberry et al. | Aug 1980 | A |
4219893 | Noiles | Sep 1980 | A |
4224696 | Murray et al. | Sep 1980 | A |
4404691 | Buning et al. | Sep 1983 | A |
4444061 | Mathias | Apr 1984 | A |
4523587 | Frey | Jun 1985 | A |
4549319 | Meyer | Oct 1985 | A |
4550448 | Kenna | Nov 1985 | A |
4566138 | Lewis et al. | Jan 1986 | A |
4659331 | Matthews et al. | Apr 1987 | A |
4662891 | Noiles | May 1987 | A |
4678470 | Nashef et al. | Jul 1987 | A |
4693721 | Ducheyne | Sep 1987 | A |
4711639 | Grundei | Dec 1987 | A |
4718909 | Brown | Jan 1988 | A |
4735625 | Davidson | Apr 1988 | A |
4778473 | Matthews et al. | Oct 1988 | A |
4789663 | Wallace et al. | Dec 1988 | A |
4790852 | Noiles | Dec 1988 | A |
4822366 | Bolesky | Apr 1989 | A |
4827919 | Barbarito et al. | May 1989 | A |
4828565 | Duthoit et al. | May 1989 | A |
4834759 | Spotorno et al. | May 1989 | A |
4840632 | Kampner | Jun 1989 | A |
4865607 | Witzel et al. | Sep 1989 | A |
4878919 | Pavlansky et al. | Nov 1989 | A |
4883448 | Kobayashi et al. | Nov 1989 | A |
4883488 | Bloebaum et al. | Nov 1989 | A |
4888021 | Forte et al. | Dec 1989 | A |
4936859 | Morscher et al. | Jun 1990 | A |
4938769 | Shaw | Jul 1990 | A |
4944757 | Martinez et al. | Jul 1990 | A |
4950298 | Gustilo et al. | Aug 1990 | A |
4960427 | Noiles | Oct 1990 | A |
4988359 | Frey et al. | Jan 1991 | A |
5019103 | Van Zile et al. | May 1991 | A |
5032134 | Lindwer | Jul 1991 | A |
5059196 | Coates | Oct 1991 | A |
5092897 | Forte | Mar 1992 | A |
5108446 | Wagner et al. | Apr 1992 | A |
5133771 | Duncan et al. | Jul 1992 | A |
5152797 | Luckman et al. | Oct 1992 | A |
5156626 | Broderick et al. | Oct 1992 | A |
5163966 | Norton et al. | Nov 1992 | A |
5176711 | Grimes | Jan 1993 | A |
5192329 | Christie et al. | Mar 1993 | A |
5197488 | Kovacevic | Mar 1993 | A |
5211664 | Tepic et al. | May 1993 | A |
5222984 | Forte | Jun 1993 | A |
5226915 | Bertin | Jul 1993 | A |
5246459 | Elias | Sep 1993 | A |
5370693 | Kelman et al. | Jun 1994 | A |
5356414 | Cohen et al. | Oct 1994 | A |
5356629 | Sander et al. | Oct 1994 | A |
5358527 | Forte | Oct 1994 | A |
5358530 | Hodorek | Oct 1994 | A |
5376123 | Klaue et al. | Dec 1994 | A |
5387241 | Hayes | Feb 1995 | A |
5405394 | Davidson | Apr 1995 | A |
5413604 | Hodge | May 1995 | A |
5443512 | Parr et al. | Aug 1995 | A |
5462563 | Shearer et al. | Oct 1995 | A |
5480444 | Incavo | Jan 1996 | A |
5480445 | Burkinshaw | Jan 1996 | A |
5489311 | Cipolletti | Feb 1996 | A |
5507830 | Demane et al. | Apr 1996 | A |
5510396 | Prewett et al. | Apr 1996 | A |
5531791 | Wolfinbarger, Jr. | Jul 1996 | A |
5549685 | Hayes | Aug 1996 | A |
5571198 | Drucker | Nov 1996 | A |
5591233 | Kelman et al. | Jan 1997 | A |
5609645 | Vinciuerra | Mar 1997 | A |
5658338 | Tullos et al. | Aug 1997 | A |
5658349 | Brooks et al. | Aug 1997 | A |
5662158 | Caldarise | Sep 1997 | A |
5683467 | Pappas | Nov 1997 | A |
5702478 | Tornier | Dec 1997 | A |
5702483 | Kwong | Dec 1997 | A |
5734959 | Krebs et al. | Mar 1998 | A |
5766256 | Oudard et al. | Jun 1998 | A |
5782925 | Collazo et al. | Jul 1998 | A |
5782929 | Sederholm | Jul 1998 | A |
5788976 | Bradford | Aug 1998 | A |
5824103 | Williams et al. | Oct 1998 | A |
5858020 | Johnson et al. | Jan 1999 | A |
5871548 | Sanders et al. | Feb 1999 | A |
5879393 | Whiteside et al. | Mar 1999 | A |
5910172 | Penenberg | Jun 1999 | A |
5931409 | Nulle et al. | Aug 1999 | A |
5957979 | Beckman et al. | Sep 1999 | A |
5958314 | Draenert | Sep 1999 | A |
5972368 | McKay | Oct 1999 | A |
5976148 | Charpenet et al. | Nov 1999 | A |
5984968 | Park | Nov 1999 | A |
5993716 | Draenert | Nov 1999 | A |
5997581 | Khalili | Dec 1999 | A |
6008432 | Taylor | Dec 1999 | A |
6013080 | Khalili | Jan 2000 | A |
6039764 | Pottenger et al. | Mar 2000 | A |
6042612 | Voydeville | Mar 2000 | A |
6053945 | O'Neil et al. | Apr 2000 | A |
6074423 | Lawson | Jun 2000 | A |
6074424 | Perrone, Jr. et al. | Jun 2000 | A |
6080195 | Colleran et al. | Jun 2000 | A |
6117175 | Bosredon | Sep 2000 | A |
6126691 | Kasra et al. | Oct 2000 | A |
6136029 | Johnson et al. | Oct 2000 | A |
6139581 | Engh et al. | Oct 2000 | A |
6139584 | Ochoa et al. | Oct 2000 | A |
6142998 | Smith et al. | Nov 2000 | A |
6162254 | Timoteo | Dec 2000 | A |
6162255 | Oyola | Dec 2000 | A |
6171342 | O'Neil et al. | Jan 2001 | B1 |
6264699 | Noiles et al. | Jul 2001 | B1 |
6290725 | Weiss et al. | Sep 2001 | B1 |
6294187 | Boyce et al. | Sep 2001 | B1 |
6328764 | Mady | Dec 2001 | B1 |
6355069 | DeCarlo, Jr. et al. | Mar 2002 | B1 |
6368352 | Camino et al. | Apr 2002 | B1 |
6423096 | Musset et al. | Jul 2002 | B1 |
6428578 | White | Aug 2002 | B2 |
6447549 | Taft | Sep 2002 | B1 |
6458161 | Gibbs et al. | Oct 2002 | B1 |
6613092 | Kana et al. | Sep 2003 | B1 |
6682568 | Despres, III et al. | Jan 2004 | B2 |
6699293 | White | Mar 2004 | B2 |
6797006 | Hodorek | Sep 2004 | B2 |
6843806 | Hayes et al. | Jan 2005 | B2 |
6875218 | Dye et al. | Apr 2005 | B2 |
6875237 | Dye et al. | Apr 2005 | B2 |
6926740 | Lewis et al. | Aug 2005 | B2 |
6946001 | Sanford et al. | Sep 2005 | B2 |
6981991 | Ferree | Jan 2006 | B2 |
7105026 | Johnson et al. | Sep 2006 | B2 |
7179295 | Kovacevic | Feb 2007 | B2 |
7179296 | Dooney | Feb 2007 | B2 |
7179297 | McLean | Feb 2007 | B2 |
7179298 | Greenlee | Feb 2007 | B2 |
D538431 | Botha | Mar 2007 | S |
7238208 | Camino et al. | Jul 2007 | B2 |
7264636 | Lewis et al. | Sep 2007 | B2 |
7291174 | German et al. | Nov 2007 | B2 |
7291177 | Gibbs | Nov 2007 | B2 |
7435263 | Barnett et al. | Oct 2008 | B2 |
7713306 | Gibbs | May 2010 | B2 |
D618800 | Mayon et al. | Jun 2010 | S |
7846212 | Lewis et al. | Dec 2010 | B2 |
7892288 | Blaylock et al. | Feb 2011 | B2 |
7892289 | Serafin, Jr. et al. | Feb 2011 | B2 |
8123814 | Meridew et al. | Feb 2012 | B2 |
8382849 | Thomas | Feb 2013 | B2 |
D684693 | Hanssen et al. | Jun 2013 | S |
8506645 | Blaylock et al. | Aug 2013 | B2 |
8535385 | Hanssen et al. | Sep 2013 | B2 |
8728168 | Hanssen et al. | May 2014 | B2 |
9044326 | Blaylock et al. | Jun 2015 | B2 |
9192476 | Thomas et al. | Nov 2015 | B2 |
9265614 | Blaylock et al. | Feb 2016 | B2 |
9539096 | Hanssen et al. | Jan 2017 | B2 |
20020072802 | O'Neil et al. | Jun 2002 | A1 |
20020120339 | Callaway et al. | Aug 2002 | A1 |
20020151984 | White | Oct 2002 | A1 |
20030065397 | Hanssen et al. | Apr 2003 | A1 |
20030153981 | Wang et al. | Aug 2003 | A1 |
20030163203 | Nycz et al. | Aug 2003 | A1 |
20030183025 | Krstic | Oct 2003 | A1 |
20030204263 | Justin et al. | Oct 2003 | A1 |
20030229398 | Iesaka | Dec 2003 | A1 |
20040034432 | Hughes et al. | Feb 2004 | A1 |
20040049270 | Gewirtz | Mar 2004 | A1 |
20040049284 | German et al. | Mar 2004 | A1 |
20040117024 | Gerbec et al. | Jun 2004 | A1 |
20040162619 | Blaylock et al. | Aug 2004 | A1 |
20040172137 | Blaylock et al. | Sep 2004 | A1 |
20050107883 | Goodfried et al. | May 2005 | A1 |
20050278034 | Johnson et al. | Dec 2005 | A1 |
20050283254 | Hayes, Jr. et al. | Dec 2005 | A1 |
20070088443 | Hanssen et al. | Apr 2007 | A1 |
20070129809 | Meridew et al. | Jun 2007 | A1 |
20080167722 | Metzger et al. | Jul 2008 | A1 |
20080281430 | Kelman et al. | Nov 2008 | A1 |
20100145452 | Blaylock et al. | Jun 2010 | A1 |
20110066252 | Hanssen et al. | Mar 2011 | A1 |
20110112651 | Blaylock et al. | May 2011 | A1 |
20110295382 | Hanssen | Dec 2011 | A1 |
20130013078 | Hanssen et al. | Jan 2013 | A1 |
20130013080 | Hanssen et al. | Jan 2013 | A1 |
20130018478 | Hanssen et al. | Jan 2013 | A1 |
20130253658 | Despres et al. | Sep 2013 | A1 |
20130304221 | Blaylock et al. | Nov 2013 | A1 |
20140039638 | Meridew et al. | Feb 2014 | A1 |
20140081418 | Hanssen et al. | Mar 2014 | A1 |
20150257890 | Blaylock et al. | Sep 2015 | A1 |
20160058560 | Blaylock et al. | Mar 2016 | A1 |
20160184103 | Fonte et al. | Jun 2016 | A1 |
20160262902 | Winslow et al. | Sep 2016 | A1 |
20170020675 | Blaylock et al. | Jan 2017 | A1 |
Number | Date | Country |
---|---|---|
2004203348 | Sep 2005 | AU |
2473633 | Sep 2005 | CA |
102010044571 | Mar 2012 | DE |
0336774 | Dec 1992 | EP |
0532585 | Apr 2000 | EP |
1004283 | May 2000 | EP |
0863731 | Apr 2001 | EP |
1004283 | Mar 2002 | EP |
1004283 | May 2005 | EP |
1913902 | Apr 2008 | EP |
2130518 | Dec 2009 | EP |
2822508 | Jan 2015 | EP |
2702651 | Sep 1994 | FR |
2772593 | Jun 1999 | FR |
2223172 | Apr 1990 | GB |
6169930 | Jun 1994 | JP |
10277069 | Oct 1998 | JP |
2000185062 | Jul 2000 | JP |
2001503283 | Mar 2001 | JP |
2001526573 | Dec 2001 | JP |
2004016822 | Jan 2004 | JP |
2005246036 | Sep 2005 | JP |
WO-9730661 | Aug 1997 | WO |
WO-9852499 | Nov 1998 | WO |
WO-9932053 | Jul 1999 | WO |
WO-0205732 | Jan 2002 | WO |
WO-2009089581 | Jul 2009 | WO |
WO-2013134333 | Sep 2013 | WO |
Entry |
---|
“U.S. Appl. No. 11/560,276, Final Office Action dated Jun. 25, 2014”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Response filed May 22, 2014 to Non Final Office Action dated Jan. 22, 2014”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Final Office Action dated Jun. 25, 2014”, 11 pgs. |
“U.S. Appl. No. 13/007,225, Response filed May 29, 2014 to Non Final Office Action dated Jan. 29, 2014”, 12 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated May 9, 2014”, 10 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated Jun. 25, 2014”, 10 pgs. |
“U.S. Appl. No. 13/619,190, Response filed May 19, 2014 to Non Final Office Action dated Dec. 18, 2013”, 12 pgs. |
“U.S. Appl. No. 13/619,190, Supplemental Preliminary Amendment filed Apr. 15, 2013”, 8 pgs. |
US 5,536,414, 10/1994, Cohen, et al. (withdrawn). |
“U.S. Appl. No. 10/225,774, Advisory Action dated Oct. 26, 2005”, 3 pgs. |
“U.S. Appl. No. 10/225,774, Examiner Interview Summary dated Mar. 17, 2005”, 4 pgs. |
“U.S. Appl. No. 10/225,774, Final Office Action dated Jun. 6, 2005”, 9 pgs. |
“U.S. Appl. No. 10/225,774, Final Office Action dated Aug. 17, 2006”, 8 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Feb. 8, 2006”, 6 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Jun. 30, 2004”, 5 pgs. |
“U.S. Appl. No. 10/225,774, Non-Final Office Action dated Dec. 8, 2004”, 6 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Mar. 7, 2005 to Non-Final Office Action dated Dec. 8, 2004”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Apr. 16, 2004 to Restriction Requirement dated Mar. 17, 2004”, 1 pg. |
“U.S. Appl. No. 10/225,774, Response filed Jun. 7, 2006 to Non-Final Office Action dated Feb. 8, 2006”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Sep. 20, 2004 to Non-Final Office Action dated Jun. 30, 2004”, 14 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Oct. 6, 2005 to Final Office Action dated Jun. 6, 2005”, 21 pgs. |
“U.S. Appl. No. 10/225,774, Response filed Nov. 15, 2006 to Final Office Action dated Aug. 17, 2006”, 1 pg. |
“U.S. Appl. No. 10/225,774, Restriction Requirement dated Mar. 17, 2014”, 6 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Apr. 20, 2010”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Aug. 21, 2008”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Final Office Action dated Aug. 27, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Feb. 2, 2009”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Mar. 30, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Non Final Office Action dated Dec. 12, 2007”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Preliminary Amendment filed Jun. 1, 2004”, 20 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jan. 4, 2007 to Restriction Requirement dated Dec. 4, 2006”, 1 pg. |
“U.S. Appl. No. 10/780,378, Response filed May 28, 2008 to Non-Final Office Action dated Dec. 12, 2007”, 11 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jun. 15, 2007 to Non-Final Office Action dated Mar. 30, 2007”, 7 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Jun. 24, 2009 to Non-Final Office Action dated Feb. 2, 2009”, 15 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Sep. 15, 2006 to Restriction Requirement dated Aug. 25, 2006”, 1 pg. |
“U.S. Appl. No. 10/780,378, Response filed Oct. 31, 2007 to Final Office Action dated Aug. 27, 2007”, 8 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Nov. 12, 2008 to Final Office Action dated Aug. 21, 2008”, 10 pgs. |
“U.S. Appl. No. 10/780,378, Response filed Dec. 22, 2009 to Restriction Requirement dated Oct. 22, 2009”, 2 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Dec. 4, 2006”, 6 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Aug. 25, 2006”, 6 pgs. |
“U.S. Appl. No. 10/780,378, Restriction Requirement dated Oct. 22, 2009”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated Jan. 16, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated Jan. 16, 2009”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Final Office Action dated May 6, 2010”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Jul. 8, 2008”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Aug. 3, 2007”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Non-Final Office Action dated Jun. 15, 2009”, 9 pgs. |
“U.S. Appl. No. 10/794,721, Notice of Allowance dated Oct. 14, 2010”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Feb. 2, 2007 to Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Apr. 14, 2009 to Final Office Action dated Jan. 16, 2009”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Jun. 16, 2008 to Final Office Action dated Jan. 16, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Sep. 28, 2009 to Non Final Office Action dated Jun. 15, 2009”, 10 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Oct. 6, 2010 to Final Office Action dated May 6, 2010”, 6 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Oct. 8, 2008 to Non Final Office Action dated Jul. 8, 2008”, 8 pgs. |
“U.S. Appl. No. 10/794,721, Response filed Nov. 8, 2007 to Non Final Office Action dated Aug. 3, 2007”, 7 pgs. |
“U.S. Appl. No. 10/794,721, Supplemental Response filed Feb. 8, 2010 to Non Final Office Action dated Jan. 12, 2010”, 2 pgs. |
“U.S. Appl. No. 10/794,721, Supplemental Response filed May 18, 2007 to Non Final Office Action dated Nov. 2, 2006”, 7 pgs. |
“U.S. Appl. No. 11/560,276 , Response filed Dec. 17, 2013 to Final Office Action dated Oct. 17, 2013”, 11 pgs. |
“U.S. Appl. No. 11/560,276, Examiner Interview Summary dated Jan. 18, 2012”, 4 pgs. |
“U.S. Appl. No. 11/560,276, Examiner Interview Summary dated Jun. 5, 2012”, 3 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Mar. 27, 2012”, 8 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Oct. 8, 2010”, 6 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Oct. 17, 2013”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Jan. 22, 2014”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Mar. 3, 2010”, 8 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Aug. 11, 2011”, 6 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Feb. 7, 2011 to Final Office Action dated Oct. 8, 2010”, 10 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Feb. 13, 2012 to Non Final Office Action dated Aug. 11, 2011”, 13 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Jun. 27, 2012 to Final Office Action dated Mar. 27, 2012”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Aug. 2, 2010 to Non Final Office Action dated Mar. 3, 2010”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Oct. 21, 2009 to Restriction Requirement dated Aug. 21, 2009”, 12 pgs. |
“U.S. Appl. No. 11/560,276, Restriction Requirement dated Aug. 21, 2009”, 7 pgs. |
“U.S. Appl. No. 12/886,297, Examiner Interview Summary dated May 6, 2013”, 3 pgs. |
“U.S. Appl. No. 12/886,297, Final Office Action dated Nov. 16, 2012”, 6 pgs. |
“U.S. Appl. No. 12/886,297, Non Final Office Action dated Apr. 22, 2013”, 6 pgs. |
“U.S. Appl. No. 12/886,297, Non Final Office Action dated Jun. 21, 2012”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Notice of Allowance dated Feb. 22, 2013”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Notice of Allowance dated Jun. 26, 2013”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Preliminary Amendment filed Sep. 20, 2010”, 10 pgs. |
“U.S. Appl. No. 12/886,297, Response filed May 7, 2012 to Restriction Requirement dated Mar. 6, 2012”, 2 pgs. |
“U.S. Appl. No. 12/886,297, Response filed Oct. 22, 2012 to Non Final Office Action dated Jun. 21, 2012”, 19 pgs. |
“U.S. Appl. No. 12/886,297, Restriction Requirement dated Mar. 6, 2012”, 6 pgs. |
“U.S. Appl. No. 12/946,132, Examiner Interview Summary dated Jun. 5, 2012”, 3 pgs. |
“U.S. Appl. No. 12/946,132, Final Office Action dated Jul. 25, 2012”, 12 pgs. |
“U.S. Appl. No. 12/946,132, Non Final Office Action dated Mar. 28, 2012”, 10 pgs. |
“U.S. Appl. No. 12/946,132, Non Final Office Action dated Oct. 11, 2013”, 7 pgs. |
“U.S. Appl. No. 12/946,132, Notice of Allowance dated Mar. 27, 2014”, 6 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Feb. 11, 2014 to Non-Final Office Action dated Oct. 11, 2013”, 19 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Jun. 27, 2012 to Non Final Office Action dated Mar. 28, 2012”, 15 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Sep. 6, 2011 to Restriction Requirement dated Aug. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 12/946,132, Response filed Sep. 24, 2012 to Final Office Action dated Jul. 25, 2012”, 16 pgs. |
“U.S. Appl. No. 12/946,132, Restriction Requirement dated Aug. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 13/007,225, Examiner Interview Summary dated May 30, 2013”, 23 pgs. |
“U.S. Appl. No. 13/007,225, Final Office Action dated Apr. 18, 2013”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Jan. 29, 2014”, 11 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Nov. 19, 2012”, 9 pgs. |
“U.S. Appl. No. 13/007,225, Preliminary Amendment filed Jan. 14, 2011”, 4 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Mar. 12, 2013 to Non-Final Office Action dated Nov. 19, 2012”, 13 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Jul. 18, 2013 to Final Office Action dated Apr. 18, 2013”, 15 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Oct. 22, 2012 to Restriction Requirement dated Sep. 20, 2012”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Restriction Requirement dated Sep. 20, 2012”, 8 pgs. |
“U.S. Appl. No. 13/007,225, Supplemental Preliminary Amendment filed Sep. 23, 2011”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Non Final Office Action dated Apr. 4, 2013”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Preliminary Amendment filed Aug. 8, 2011”, 8 pgs. |
“U.S. Appl. No. 13/205,163, Response filed Feb. 21, 2013 to Restriction Requirement dated Jan. 24, 2013”, 10 pgs. |
“U.S. Appl. No. 13/205,163, Response filed Jul. 3, 2013 to Non Final Office Action dated Apr. 4, 2013”, 13 pgs. |
“U.S. Appl. No. 13/205,163, Restriction Requirement dated Jan. 24, 2013”, 6 pgs. |
“U.S. Appl. No. 13/416,857, Response filed May 24, 2013 to Non Final Office Action dated Feb. 25, 2013”, 15 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Dec. 13, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Nov. 8, 2013 to Restriction Requirement dated Oct. 23, 2013”, 8 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Apr. 14, 2014 to Non-Final Office Action dated Dec. 13, 2013”, 13 pgs. |
“U.S. Appl. No. 13/619,091, Restriction Requirement dated Oct. 23, 2013”, 5 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Dec. 13, 2013”, 9 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Nov. 8, 2013 to Restriction Requirement dated Oct. 17, 2013”, 8 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Apr. 14, 2014 to Non-Final Office Action dated Dec. 13, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,134, Restriction Requirement dated Oct. 17, 2013”, 5 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Dec. 18, 2013”, 11 pgs. |
“U.S. Appl. No. 13/619,190, Preliminary Amendment filed Oct. 29, 2012”, 8 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Nov. 18, 2013 to Restriction requirement dated Oct. 18, 2013”, 7 pgs. |
“U.S. Appl. No. 13/619,190, Restriction Requirement dated Oct. 18, 2013”, 7 pgs. |
“U.S. Appl. No. 29/379,094, Application filed Nov. 15, 2010”, 6 pgs. |
“U.S. Appl. No. 29/379,094, Notice of Allowance dated Feb. 28, 2013”, 12 pgs. |
“U.S. Appl. No. 29/379,094, Response filed Nov. 21, 2012 to Restriction Requirement dated Oct. 23, 2012”, 4 pgs. |
“U.S. Appl. No. 29/379,094, Restriction Requirement dated Oct. 23, 2012”, 7 pgs. |
“Australian Application No. 2004203348, Office Action dated Jan. 13, 2010”, 3 pgs. |
“Canadian Application No. 2,473,633, Office Action dated Mar. 12, 2010”, 3 pgs. |
“European Application No. 04254352.0, European Search Report dated Jun. 22, 2005”, 3 pgs. |
“European Application Serial No. 04254352.0, Examination Notification Art. 94(3) dated Mar. 10, 2014”, 5 pgs. |
“European Application Serial No. 04254352.0, Examination Notification Art. 94(3) dated Apr. 22, 2013”, 5 pgs. |
“European Application Serial No. 04254352.0, Response filed Sep. 2, 2013 to Examination Notification Art. 94(3) dated Apr. 22, 2013”, 10 pgs. |
“Forbes Magazine Ranks Zimmer Holdings Among the ‘Best Managed Companies in America’”, PR Newswire, (Jan. 23, 2004), 2 pgs. |
“International Application Serial No. PCT/US2013/029251, International Search Report dated Jun. 19, 2013”, 5 pgs. |
“International Application Serial No. PCT/US2013/029251, Written Opinion dated Jun. 19, 2013”, 7 pgs. |
“Japanese Application No. 2004-216179, Office Action dated May 26, 2009”, (W/ English Translation), 8 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated May 1, 2015”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Dec. 5, 2014”, 14 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Apr. 6, 21015 to Non-Final Office Action dated Dec. 5, 2014”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Sep. 1, 2015 to Final Office Action dated May 1, 2015”, 28 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 13 pgs. |
“U.S. Appl. No. 13/007,225, Non Final Office Action dated Dec. 11, 2014”, 6 pgs. |
“U.S. Appl. No. 13/007,225, Notice of Allowance dated Apr. 6, 2015”, 10 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Mar. 3, 2015 to Non-Final Office Action dated Dec. 11, 2014”, 13 pgs. |
“U.S. Appl. No. 13/007,225, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 16 pgs. |
“U.S. Appl. No. 13/205,163, Notice of Allowance dated Aug. 5, 2013”, 9 pgs. |
“U.S. Appl. No. 13/416,857, Non Final Office Action dated Feb. 25, 2013”, 17 pgs. |
“U.S. Appl. No. 13/619,091, Advisory Action dated Sep. 17, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,091, Examiner Interview Summary dated Sep. 8, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Mar. 10, 2015”, 18 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Jul. 1, 2015”, 17 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Dec. 4, 2014”, 15 pgs. |
“U.S. Appl. No. 13/619,091, Preliminary Amendment filed Aug. 26, 2013”, 7 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Jan. 21, 2015 to Non-Final Office Action dated Dec. 4, 2014”, 31 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Jun. 10, 2015 to Final Office Action dated Mar. 10, 2015”, 32 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Sep. 9, 2014 to Final Office Action dated May 9, 2014”, 12 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Oct. 9, 2014 to Advisory Action dated Sep. 17, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,134, Advisory Action dated Sep. 18, 2014”, 3 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Mar. 10, 15”, 20 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Jul. 6, 2015”, 19 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Dec. 5, 2014”, 18 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Jan. 22, 2015 to Non-Final Office Action dated Dec. 5, 2014”, 32 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Jun. 10, 2015 to Non-Final Office Action dated Mar. 10, 2015”, 33 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Sep. 8, 2014 to Final Office Action dated May 8, 2014”, 13 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Oct. 9, 2014 to Advisory Action dated Sep. 18, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated May 12, 2015”, 16 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Dec. 4, 2014”, 14 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Apr. 6, 2015 to Non-Final Office Action dated Dec. 4, 2014”, 17 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Sep. 1, 2015 to Final Office Action dated May 12, 2015”, 30 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Oct. 27, 2014 to Final Office Action dated Jun. 25, 2014”, 13 pgs. |
“U.S. Appl. No. 13/944,441, Non Final Office Action dated Apr. 20, 2015”, 12 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Mar. 30, 2015 to Restriction Requirement dated Feb. 2, 2015”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Aug. 20, 2015 to Non Final Office Action dated Apr. 20, 2015”, 16 pgs. |
“U.S. Appl. No. 13/944,441, Restriction Requirement dated Feb. 2, 2015”, 6 pgs. |
“U.S. Appl. No. 14/085,040, Non Final Office Action dated Jul. 21, 2015”, 12 pgs. |
“U.S. Appl. No. 14/085,040, Response to Restriction Requirement filed Jun. 22, 2015 to Restriction Requirement dated Apr. 22, 2015”, 8 pgs. |
“U.S. Appl. No. 14/085,040, Restriction Requirement dated Apr. 22, 2015”, 6 pgs. |
“U.S. Appl. No. 14/722,701, Preliminary Amendment filed Jun. 16, 2015”, 9 pgs. |
“International Application Serial No. PCT/US2013/029251, International Preliminary Report on Patentability dated Sep. 18, 2014”, 9 pgs. |
“U.S. Appl. No. 11/560,276, Final Office Action dated Feb. 26, 2016”, 17 pgs. |
“U.S. Appl. No. 11/560,276, Non Final Office Action dated Sep. 25, 2015”, 16 pgs. |
“U.S. Appl. No. 11/560,276, Response filed Jan. 25, 2016 to Non-Final Office Action dated Sep. 25, 2015”, 33 pgs. |
“U.S. Appl. No. 13/619,091, Appeal Brief filed Feb. 11, 2016”, 103 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Dec. 2, 2015”, 19 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Nov. 10, 2015 to Non-Final Office Action dated Jul. 1, 2015”, 37 pgs. |
“U.S. Appl. No. 13/619,134, Appeal Brief filed Feb. 4, 2016”, 72 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Dec. 2, 2015”, 21 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Nov. 10, 2015 to Non Final Office Action dated Jul. 6, 2015”, 39 pgs. |
“U.S. Appl. No. 13/619,190, Final Office Action dated Mar. 1, 2016”, 18 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Sep. 25, 2015”, 17 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Jan. 25, 2016 to Non-Final Office Action dated Sep. 25, 2015”, 35 pgs. |
“U.S. Appl. No. 13/944,441, Final Office Action dated Sep. 17, 2015”, 7 pgs. |
“U.S. Appl. No. 13/944,441, Notice of Allowance dated Oct. 14, 2015”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Preliminary Amendment filed Jul. 19, 2013”, 8 pgs. |
“U.S. Appl. No. 13/944,441, Response filed Oct. 5, 2015 to Final Office Action dated Sep. 17, 2015”, 8 pgs. |
“U.S. Appl. No. 14/085,040, Final Office Action dated Nov. 12, 2015”, 14 pgs. |
“U.S. Appl. No. 14/085,040, Non Final Office Action dated Mar. 28, 2016”, 10 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Mar. 7, 2016 to Final Office Action dated Nov. 12, 2015”, 7 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Oct. 21, 2015 to Non Final Office Action dated Jul. 21, 2015”, 34 pgs. |
“U.S. Appl. No. 14/722,701, Non Final Office Action dated May 6, 2016”, 18 pgs. |
“U.S. Appl. No. 14/936,929, Preliminary Amendment filed Nov. 11, 2015”, 7 pgs. |
“U.S. Appl. No. 13/619,091, Non Final Office Action dated Jun. 22, 2016”, 22 pgs. |
“U.S. Appl. No. 13/619,134, Non Final Office Action dated Jun. 22, 2016”, 24 pgs. |
“U.S. Appl. No. 14/085,040, Response filed Jul. 28, 2016 to Non Final Office Action dated Mar. 28, 2016”, 11 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Aug. 3, 2016 to Non Final Office Action dated May 6, 2016”, 15 pgs. |
“European Application Serial No. 13715785.5, Decision to Grant dated Feb. 4, 2016”, 2 pgs. |
“European Application Serial No. 13715785.5, Office Action dated Sep. 7, 2015”, 26 pgs. |
“European Application Serial No. 13715785.5, Response filed May 27, 2015 to Communication pursuant to Rules 161(2) and 162 EPC dated Nov. 20, 2014”, 22 pgs. |
“U.S. Appl. No. 11/560,276, Appeal Brief filed Oct. 27, 2016”, 68 pgs. |
“U.S. Appl. No. 11/560,276, Appellants' Reply Brief filed Feb. 1, 2017 to Examiner's Answer mailed Dec. 1, 2016”, 15 pgs. |
“U.S. Appl. No. 13/619,091, Appeal Brief filed Dec. 19, 2016”, 113 pgs. |
“U.S. Appl. No. 13/619,091, Final Office Action dated Oct. 11, 2016”, 21 pgs. |
“U.S. Appl. No. 13/619,091, Response filed Sep. 22, 2016 to Non Final Office Action dated Jun. 22, 2016”, 34 pgs. |
“U.S. Appl. No. 13/619,134, Appeal Brief filed Dec. 19, 2016”, 112 pgs. |
“U.S. Appl. No. 13/619,134, Final Office Action dated Oct. 11, 2016”, 25 pgs. |
“U.S. Appl. No. 13/619,134, Response filed Sep. 22, 2016 to Non-Final Office Action dated Jun. 22, 2016”, 35 pgs. |
“U.S. Appl. No. 13/619,190, Non Final Office Action dated Oct. 27, 2016”, 14 pgs. |
“U.S. Appl. No. 13/619,190, Response filed Sep. 1, 2016 to Final Office Action dated Mar. 1, 2016”, 29 pgs. |
“U.S. Appl. No. 14/085,040, Notice of Allowance dated Aug. 31, 2016”, 6 pgs. |
“U.S. Appl. No. 14/722,701, Advisory Action dated Nov. 9, 2016”, 3 pgs. |
“U.S. Appl. No. 14/722,701, Final Office Action dated Sep. 15, 2016”, 12 pgs. |
“U.S. Appl. No. 14/722,701, Non Final Office Action dated Dec. 1, 2016”, 8 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Feb. 24, 2017 to Non-Final Office Action dated Dec. 1, 2016”, 12 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Oct. 31, 2016 to Final Office Action dated Sep. 15, 2016”, 14 pgs. |
“U.S. Appl. No. 14/722,701, Response filed Nov. 11, 2016 to Final Office Action dated Sep. 15, 2016”, 14 pgs. |
“U.S. Appl. No. 14/936,929, Non Final Office Action dated Feb. 15, 2017”, 12 pgs. |
“U.S. Appl. No. 14/936,929, Response filed Jan. 20, 2017 to Restriction Requirement dated Dec. 14, 2016”, 7 pgs. |
“U.S. Appl. No. 14/936,929, Restriction Requirement dated Dec. 14, 2016”, 6 pgs. |
“U.S. Appl. No. 15/285,689, Preliminary Amendment filed Oct. 6, 2016”, 12 pgs. |
Neer, Charles S., et al., “Glenoid Bone-Grafting in Total Shoulder Arthroplasty”, The Journal of Bone and Joint Surgery, vol. 70-A, No. 8,, (Sep. 1998), pp. 1154-1162. |
Walch, Giles, et al., “Morphological Study of the Glenoid in Primary Glenohumeral Osteoarthritis”, The Journal of Arthroplasty, 14(6), (1999), 756-760. |
Number | Date | Country | |
---|---|---|---|
20140249637 A1 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
60315148 | Aug 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10225774 | Aug 2002 | US |
Child | 11560276 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12946132 | Nov 2010 | US |
Child | 14278916 | US | |
Parent | 11560276 | Nov 2006 | US |
Child | 12946132 | US |